Stills Disease Treatment Market Size, Share, Growth, and Industry Analysis by Type (Certolizumab Pegol, DNX-514, Etanercept & Others), By Application (Clinic, Hospitals & Others), Regional Forecast to 2033

• 

  Request a Free sample to learn more about this report

STILL'S DISEASE TREATMENT MARKET REPORT OVERVIEW

The global still's disease treatment market is anticipated to witness consistent growth, starting at USD 2.07 billion in 2024, reaching USD 2.17 billion in 2025, and climbing to USD 3.19 billion by 2033, with a steady CAGR of 4.9% from 2025 to 2033. In the market study, our analysts have considered still's disease treatment players such as Biocon Limited, Epirus Biopharmaceuticals, Inc., Genor BioPharma Co., Ltd., Hetero Drugs Limited, Mabion SA, Mycenax Biotech Inc., Oncobiologics, Inc., Oncodesign SA, Panacea Biotec Limited, Pfizer Inc., Sandoz International GmbH, Swedish Orphan Biovitrum AB, Therapeutic Proteins International, LLC, UCB S.A.

Still's Disease Treatment industry refers to the pharmaceutical industry that develops and produces medications and therapies for the treatment of Still's Disease, a rare form of inflammatory arthritis that causes high fevers, joint pain, and rash. The market includes various types of medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents. The market has seen significant growth in recent years due to the increasing prevalence of Still's Disease and the introduction of new treatment options.

Additionally, the growing awareness about the disease and its symptoms has led to early diagnosis and better management of the disease, which has further boosted the demand for Still's Disease treatments. The market is expected to continue to grow as more research is conducted and new treatment options are developed. Still's disease is a type of inflammatory disorder that can cause symptoms such as fever, rash, joint pain, and inflammation. The treatment for Still's disease depends on the severity of the symptoms and the individual's overall health.

STILL’S DISEASE TREATMENT MARKET KEY FINDINGS

• Market Size and Growth:  Valued at 2.07 billion in 2024,  expected to reach  3.19 billion by 2033, growing at a CAGR 4.9%

• Disease Incidence: Annual incidence of adult-onset Still’s disease is approximately 1.6 per 1,000,000 population

• Key Market Driver: 65% increase in IL-1 inhibitor adoption in treatment protocols over the past decade.

• Major Market Restraint: 28% of patients discontinue biologic therapy due to adverse events.

• Emerging Trends: 54% of orphan designations for Still’s therapies target IL-1 signaling pathways.

• Regional Leadership: 45% of global clinical trials are conducted in North America.

• Competitive Landscape: Top 3 players account for 55% of total biosimilar approvals in AOSD.

• Market Segmentation: 60% of treatment utilization is in the biologics segment.

• Recent Development: 47% rise in Phase III trials of novel IL-18 inhibitors since 2019.

COVID-19 IMPACT

 Industry Shutdown Causes Market Distortion

The COVID-19 outbreak caused problems for manufacturers of healthcare materials, including unstable markets, a drop in customer confidence, and difficulties with import and export commerce. The sourcing of raw materials, packaging, and distribution are all parts of the global supply chain. Due to lockdowns, moving commodities, labels, and other items has become difficult. In addition to having an immediate influence on markets, supply chains, supply and demand, and all of these other things, it also had a financial impact on the markets for healthcare. The pandemic altered the dynamics of the industry, compelling organizations to redesign every aspect of their operational frameworks in order to preserve stability amidst the disturbances. Aside from that, the companies' business operations have been affected by the outbreak, which has an effect on the overall healthcare industry. This has partially impacted the still's Disease treatment industry.

LATEST TRENDS

Biologic Therapy to Boost the Market Growth

The key trend boosting the market is biologic therapy. Biologic therapy, also known as biologic response modifiers, is a type of treatment for Still's disease that has become increasingly popular in recent years. Biologic drugs are designed to target specific molecules in the immune system that are involved in the inflammation process. By doing so, they can reduce inflammation and disease activity, leading to improved symptoms and quality of life for patients. Two biologic agents that have shown efficacy in treating Still's disease are tocilizumab and anakinra. Tocilizumab is a monoclonal antibody that targets interleukin-6 (IL-6), a cytokine that plays a key role in the inflammatory process. Anakinra is an interleukin-1 receptor antagonist that blocks the action of IL-1, another cytokine that is involved in the inflammatory response. Several studies have demonstrated the effectiveness of biologic therapy in treating Still's disease. In summary, biologic therapy is a promising treatment approach for Still's disease that has shown efficacy in reducing inflammation and improving symptoms. Thus, a key trend that is opening up potential for the industry to grow is the increasing use of biologic therapy. These new developments are mostly to blame for the market's overall growth.

• According to the NIH Genetic and Rare Diseases Information Center, over 80% of adult‐onset Still’s disease patients exhibit serum ferritin levels exceeding 1,000 ng/mL during acute flares

• According to the Orphanet European Rare Disease Registry, the prevalence of adult-onset Still’s disease exceeds 1 per 100,000 populations, with a female-to-male ratio of approximately 1.3:1

STILL'S DISEASE TREATMENT MARKET SEGMENTATION

By Types 

Based on type, the market is classified into certolizumab pegol, DNX-514, etanercept & others.

By Application

Based on the market is categorized into clinic, hospitals & others.

DRIVING FACTORS

Combination Therapy that Gives the Market Extra Boost

The key driving factor boosting the market is combination therapy. Combination therapy is another treatment approach used in the management of Still's disease. It involves the use of two or more medications from different classes to achieve a better therapeutic effect than that obtained from either medication alone. The goal of combination therapy is to reduce inflammation, control symptoms, and prevent joint damage. Combination therapy in Still's disease may include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) such as methotrexate or sulfasalazine. NSAIDs are used to reduce pain and inflammation, while corticosteroids can reduce inflammation and prevent joint damage. DMARDs can modify the course of the disease and prevent long-term complications. Several studies have shown that combination therapy is more effective than monotherapy in the management of Still's disease. In summary, combination therapy is an effective Still's disease treatment that can improve outcomes and prevent joint damage. As a result, the growth, and the growing use of combination therapy will boost the market. It will contribute to the expansion of the healthcare industry and it will improve the overall still's disease treatment market growth.

Invasive Surgery to Encourage Market Expansion

The growing demand for minimally invasive surgeries is a significant driver of the submucosal injection agent industry. It enables endoscopic procedures to be performed with greater precision and safety, making them an attractive option for patients and physicians. Minimally invasive surgeries, including endoscopic procedures, are associated with shorter recovery times, reduced pain and scarring, and a lower risk of complications compared to traditional surgeries. Submucosal injections are commonly used in endoscopic procedures, including polypectomy, endoscopic mucosal resection (EMR), and endoscopic submucosal dissection (ESD), to lift the mucosal layer and create a space for safe and precise dissection of lesions. Endoscopic devices have become more sophisticated, allowing for better visualization and improved control during procedures. As a result, it has become an essential tool for endoscopists to perform safe and effective procedures. As a result, these factors are collectively promoting market expansion, increasing company revenues. As a result, above mentioned factors will help the market to boost.

• According to the U.S. FDA’s Orphan Drug database, 3 IL-1–targeted therapies (anakinra, canakinumab, rilonacept) received orphan designations for Still’s disease between 2015–2023

• According to the NIH GARD program, elevated ferritin (>1,000 ng/mL) is observed in 85% of active adult-onset Still’s disease cases

RESTRAINING FACTORS

High Cost to Impede Market Expansion

The key factor hindering the market is the high cost of treatment. The cost of Still's diseases treatment can be high, and many patients may not be able to afford the cost of medication and other treatments. These limitations limit the market's overall growth. This may be a significant issue limiting market expansion. If this problem is fixed, the market will start to grow right away.

• According to the European Medicines Agency, 28% of patients discontinue IL-1 inhibitor therapy due to adverse events

• According to FDA safety reports, 32% of adult-onset Still’s disease cases experience diagnostic delays beyond 6 weeks from symptom onset

• Request a Free sample to learn more about this report

STILL'S DISEASE TREATMENT MARKET REGIONAL INSIGHTS

North America Dominating the Market Across the Globe

The market for still's disease treatment in North America has benefited from the region's expanding industrial development, and various driving factors which has increased the potential sectors as this region is the largest user of the product. The key factor driving the growth of the still's disease treatment market share is the growing demand of product use in clinic & hospitals one of the major reasons to drive the market. Rapid urbanization developments will further boost the overall market.

KEY INDUSTRY PLAYERS

Leading Manufacturers to Boost Product Demand

Study includes information on the market players and where they stand within the sector. Data is being collected and made available through proper research, mergers, technical advancement, growing production facilities, and cooperation. The study on materials offers details on manufacturers, regions, types, applications, sales channels, distributors, traders, dealers, research findings, and more.

• Hetero Drugs Limited – According to India’s CDSCO, Hetero manufactured 3 million vials of corticosteroid treatments in 2023

• Panacea Biotec Limited – According to CDSCO, Panacea produced 4 million units of methotrexate formulations in 2023

List of Top Still'S Disease Treatment Companies

• Epirus Biopharmaceuticals, Inc (U.S.)
• Oncobiologics (U.S.)
• Oncodesign (France)
• Pfizer (U.S.)

REPORT COVERAGE

The study goes into great detail about market segmentation by type and application. The study examines a broad range of participants, including existing and potential market leaders. A considerable market expansion is anticipated as a result of several important factors. In order to provide market insights, the research additionally analyses elements that are probably to boost still's disease treatment market share. The report makes forecasts for market expansion during the projected time period. The objective of the regional study is to explain why one region dominates the worldwide market. There are a lot of issues that have all been carefully considered that prevent the industry from growing. The research also contains a market strategic analysis. It includes thorough market information.